InAADR

Protein Information

Protein Name: Estrogen receptor (P03372)
Gene Name: ESR1
Description:
PDB ID: 1A52
Protein Family: PF12743, PS00031
Protein Category: Transcription Factor

This panel provides drug-protein interaction and their ADRs along with references

Interacting Drugs Toxicity Mechanism Reference
Conjugated Estrogens Increase In Bone Mineral Density Increase in bone mineral density [ ADR Type 1 ] Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women
Estradiol Increase In High-Density Lipoprotein Cholesterol Increase in high-density lipoprotein cholesterol [ ADR Type 1 ] Estrogen-receptor polymorphism and hormone-replacement therapy
Estradiol Oncogenesis Interacting with an Sp1(N)30 ERE half-site (?) motif in which both ER and Sp1 bind promoter DNA,EXERT oncogenesis in multiple tissues. [ ADR Type 2 ] Transcriptional activation of transforming growth factor alpha by estradiol: requirement for both a GC-rich site and an estrogen response element half-site
Medroxyprogesterone Mammary Adenocarcinoma Progesterone receptors (PR) and estrogen receptors (ER) were detected only in epithelial-enriched cultures from 7 day-MPA-treated mice,suggesting MPA-induced mammary adenocarcinoma may be mediated or potentiated by serum factors [ ADR Type 2 ] Effect of medroxyprogesterone acetate (MPA) and serum factors on cell proliferation in primary cultures of an MPA-induced mammary adenocarcinoma

This panel provides information on drug category

Toxicity Source
Acne Large-scale prediction and testing of drug activity on side-effect targets
Blood Urea Increased Large-scale prediction and testing of drug activity on side-effect targets
Bone Disorder Large-scale prediction and testing of drug activity on side-effect targets
Breast Pain Large-scale prediction and testing of drug activity on side-effect targets
Chloasma Large-scale prediction and testing of drug activity on side-effect targets
Depression Large-scale prediction and testing of drug activity on side-effect targets
Electrolyte Imbalance Large-scale prediction and testing of drug activity on side-effect targets
Embolism Arterial Large-scale prediction and testing of drug activity on side-effect targets
Endometrial Cancer Large-scale prediction and testing of drug activity on side-effect targets
Endometrial Hyperplasia Large-scale prediction and testing of drug activity on side-effect targets
Epiphyses Premature Fusion Large-scale prediction and testing of drug activity on side-effect targets
Erythema Multiforme Large-scale prediction and testing of drug activity on side-effect targets
Fibrocystic Breast Disease Large-scale prediction and testing of drug activity on side-effect targets
Gynaecomastia Large-scale prediction and testing of drug activity on side-effect targets
Hepatic Function Abnormal Large-scale prediction and testing of drug activity on side-effect targets
Hypercalcaemia Large-scale prediction and testing of drug activity on side-effect targets
Jaundice Large-scale prediction and testing of drug activity on side-effect targets
Menstrual Disorder Large-scale prediction and testing of drug activity on side-effect targets
Metrorrhagia Large-scale prediction and testing of drug activity on side-effect targets
Neoplasm Large-scale prediction and testing of drug activity on side-effect targets
Oedema Large-scale prediction and testing of drug activity on side-effect targets
Osteoporosis Association of a G2014A transition in exon 8 of the estrogen receptor-alpha gene with postmenopausal osteoporosis
Porphyria Non-Acute Large-scale prediction and testing of drug activity on side-effect targets
Sodium Retention Large-scale prediction and testing of drug activity on side-effect targets
Urticaria Large-scale prediction and testing of drug activity on side-effect targets
Uterine Inflammation Large-scale prediction and testing of drug activity on side-effect targets
Weight Increased Large-scale prediction and testing of drug activity on side-effect targets

InAADR: Drug-Protein-ADRs database